Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea

Liver International

Volumn 33, Issue 5, 2013, Pages 706-713

  Yoo, Eun Jin ^a   Kim, Beom Kyung ^a   Kim, Seung Up ^a   Park, Jun Yong ^a   Kim, Do Young ^a   Ahn, Sang Hoon ^a   Han, Kwang Hyub ^a   Chon, Chae Yoon ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Enhanced liver fibrosis; Healthy individual; Liver fibrosis; Normal value; Screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM ALBUMIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ALGORITHM; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DONOR; ENHANCED LIVER FIBROSIS; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; HEART DISEASE; HEPATITIS B; HEPATITIS C; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; LIVER FIBROSIS; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; NORMAL HUMAN; PROTHROMBIN TIME; SOUTH KOREA; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; HUMANS; LINEAR MODELS; LIVER CIRRHOSIS; MALE; REFERENCE VALUES; REPUBLIC OF KOREA; SEX FACTORS;

EID: 84876077203     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12136     Document Type: Article

References (37)

1. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9, 9 e1-3.
2. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
3. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
4. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.
5. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
6. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
7. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13.
8. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 23-31.
9. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
10. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-57.
11. Kim SU, Ahn SH, Park JY, et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol 2009; 43: 267-71.
12. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-302 e4.
13. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136: 160-7.
14. Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-84.
15. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266-71.
16. American Gastroenterological Association. Medical position statement: evaluation of liver chemistry tests. Gastroenterology 2002; 123: 1364-6.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
18. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
19. Gumusay O, Ozenirler S, Atak A, et al. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2012; 43: 228-37.
20. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
21. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.
22. Yoneda M, Fujita K, Inamori M, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56: 1330-1.
23. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
24. Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10: 103.
25. Guechot J, Trocme C, Renversez JC, Sturm N, Zarski JP. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med 2012; 50: 693-9.
26. Kim BK, Kim HS, Park JY, et al. Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. PLoS ONE 2012; 7: e41964.
27. Sohn W, Jun DW, Kwak MJ, et al. The upper limit of normal of serum alanine and aspartate aminotransferase levels in Korea. J Gastroenterol Hepatol 2012; 28: 522-9.
28. Kim BK, Kim SU, Choi GH, et al. "Normal" liver stiffness values differ between men and women: a prospective study for healthy living liver and kidney donors in a native Korean population. J Gastroenterol Hepatol 2012; 27: 781-8.
29. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res 2007; 37: 239-47.
30. Freudenberger T, Rock K, Dai G, et al. Estradiol inhibits hyaluronic acid synthase 1 expression in human vascular smooth muscle cells. Basic Res Cardiol 2011; 106: 1099-109.
31. Claassen H, Steffen R, Hassenpflug J, et al. 17beta-estradiol reduces expression of MMP-1, -3, and -13 in human primary articular chondrocytes from female patients cultured in a three dimensional alginate system. Cell Tissue Res 2010; 342: 283-93.
32. Das K, Sarkar R, Ahmed SM, et al. 'Normal' liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. Hepatology 2012; 55: 584-93.
33. Roulot D, Czernichow S, Le Clesiau H, et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-13.
34. Kumar M, Sharma P, Garg H, et al. Transient elastographic evaluation in adult subjects without overt liver disease: influence of alanine aminotransferase levels. J Gastroenterol Hepatol 2011; 26: 1318-25.
35. Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62.
36. Fontana RJ, Goodman ZD, Dienstag JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47: 789-98.s.
37. Usluer G, Erben N, Aykin N, et al. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis 2012; 31: 1873-8.